Darrell Irvine developed “amphiphile” vaccines that hitch a ride on albumin molecules to the lymph nodes, where they teach the immune system to fight cancer. Elicio Therapeutics, the MIT spinout, is testing the vaccines in clinical trials and has produced promising early results in treating pancreatic cancer. Therapeutic cancer vaccines have not lived up to their potential due to weak immune responses. A new approach developed by researchers is showing promising results in clinical trials. The vaccine has the potential to fill a need in cancer treatment, specifically for pancreatic cancer, as it targets the mutations driving 90-95% of cases. Preliminary results have shown a strong immune response in patients.
Source link